Literature DB >> 26239973

Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis.

S T de Macedo-Silva1, G Visbal2, J A Urbina3, W de Souza4, J C F Rodrigues5.   

Abstract

Leishmaniases comprise a spectrum of diseases caused by protozoan parasites of the Leishmania genus. Treatments available have limited safety and efficacy, high costs, and difficult administration. Thus, there is an urgent need for safer and more-effective therapies. Most trypanosomatids have an essential requirement for ergosterol and other 24-alkyl sterols, which are absent in mammalian cells. In previous studies, we showed that Leishmania amazonensis is highly susceptible to aryl-quinuclidines, such as E5700, which inhibit squalene synthase, and to the azoles itraconazole (ITZ) and posaconazole (POSA), which inhibit C-14α-demethylase. Herein, we investigated the antiproliferative, ultrastructural, and biochemical effects of combinations of E5700 with ITZ and POSA against L. amazonensis. Potent synergistic antiproliferative effects were observed against promastigotes, with fractional inhibitory concentration (FIC) ratios of 0.0525 and 0.0162 for combinations of E5700 plus ITZ and of E5700 plus POSA, respectively. Against intracellular amastigotes, FIC values were 0.175 and 0.1125 for combinations of E5700 plus ITZ and E5700 plus POSA, respectively. Marked alterations of the ultrastructure of promastigotes treated with the combinations were observed, in particular mitochondrial swelling, which was consistent with a reduction of the mitochondrial transmembrane potential, and an increase in the production of reactive oxygen species. We also observed the presence of vacuoles similar to autophagosomes in close association with mitochondria and an increase in the number of lipid bodies. Both growth arrest and ultrastructural/biochemical alterations were strictly associated with the depletion of the 14-desmethyl endogenous sterol pool. These results suggest the possibility of a novel combination therapy for the treatment of leishmaniasis.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239973      PMCID: PMC4576079          DOI: 10.1128/AAC.01150-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  58 in total

1.  Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana.

Authors:  Julio A Urbina; Juan Luis Concepcion; Salomé Rangel; Gonzalo Visbal; Renee Lira
Journal:  Mol Biochem Parasitol       Date:  2002 Nov-Dec       Impact factor: 1.759

Review 2.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

3.  A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis.

Authors:  M Nassiri-Kashani; A Firooz; A Khamesipour; F Mojtahed; M Nilforoushzadeh; H Hejazi; N Bouzari; Y Dowlati
Journal:  J Eur Acad Dermatol Venereol       Date:  2005-01       Impact factor: 6.166

4.  Sterol methenyl transferase inhibitors alter the ultrastructure and function of the Leishmania amazonensis mitochondrion leading to potent growth inhibition.

Authors:  Juliany C F Rodrigues; Celene F Bernardes; Gonzalo Visbal; Julio A Urbina; Anibal E Vercesi; Wanderley de Souza
Journal:  Protist       Date:  2007-08-24

5.  Host cell lipid bodies triggered by Trypanosoma cruzi infection and enhanced by the uptake of apoptotic cells are associated with prostaglandin E₂ generation and increased parasite growth.

Authors:  Heloisa D'Avila; Célio G Freire-de-Lima; Natalia R Roque; Livia Teixeira; Christina Barja-Fidalgo; Adriana R Silva; Rossana C N Melo; George A Dosreis; Hugo C Castro-Faria-Neto; Patrícia T Bozza
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

6.  VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.

Authors:  Galina I Lepesheva; Tatiana Y Hargrove; Girish Rachakonda; Zdzislaw Wawrzak; Sébastien Pomel; Sandrine Cojean; Pius N Nde; W David Nes; Charles W Locuson; M Wade Calcutt; Michael R Waterman; J Scott Daniels; Philippe M Loiseau; Fernando Villalta
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

7.  Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes.

Authors:  H Rangel; F Dagger; A Hernandez; A Liendo; J A Urbina
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Ergosterol biosynthesis and drug development for Chagas disease.

Authors:  Julio A Urbina
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

9.  Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.

Authors:  Xenón Serrano-Martín; Gilberto Payares; Marisel De Lucca; Juan Carlos Martinez; Alexis Mendoza-León; Gustavo Benaim
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

Review 10.  Management of trypanosomiasis and leishmaniasis.

Authors:  Michael P Barrett; Simon L Croft
Journal:  Br Med Bull       Date:  2012-11-07       Impact factor: 4.291

View more
  11 in total

1.  Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Authors:  April C Joice; Sihyung Yang; Abdelbasset A Farahat; Heidi Meeds; Mei Feng; Junan Li; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  In Vitro Effect of Pitavastatin and Its Synergistic Activity with Isavuconazole against Acanthamoeba castellanii.

Authors:  Hye Jee Hahn; Jose Ignacio Escrig; Brian Shing; Anjan Debnath
Journal:  Pathogens       Date:  2020-08-21

3.  Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, and Efficacy in Experimental Cutaneous Leishmaniasis.

Authors:  Valter Viana Andrade-Neto; Edézio Ferreira Cunha-Júnior; Marilene Marcuzzo do Canto-Cavalheiro; Geórgia Correa Atella; Talita de Almeida Fernandes; Paulo Roberto Ribeiro Costa; Eduardo Caio Torres-Santos
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Synthesis and Biological Activity of Novel Zinc-Itraconazole Complexes in Protozoan Parasites and Sporothrix spp.

Authors:  Jose Aleixo de Azevedo-França; Renato Granado; Sara Teixeira de Macedo Silva; Gabrielle Dos Santos-Silva; Sandra Scapin; Luana P Borba-Santos; Sonia Rozental; Wanderley de Souza; Érica S Martins-Duarte; Emile Barrias; Juliany Cola Fernandes Rodrigues; Maribel Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

5.  CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).

Authors:  Anjan Debnath; Claudia M Calvet; Gareth Jennings; Wenxu Zhou; Alexander Aksenov; Madeline R Luth; Ruben Abagyan; W David Nes; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2017-12-28

6.  Isobenzofuranone derivative JVPH3, an inhibitor of L. donovani topoisomerase II, disrupts mitochondrial architecture in trypanosomatid parasites.

Authors:  Somenath Roy Chowdhury; Joseane Lima Prado Godinho; Jayaraman Vinayagam; Aline Araujo Zuma; Sara Teixeira De Macedo Silva; Parasuraman Jaisankar; Juliany Cola Fernandes Rodrigues; Wanderley De Souza; Hemanta K Majumder
Journal:  Sci Rep       Date:  2018-08-09       Impact factor: 4.379

7.  Enzymatic chokepoints and synergistic drug targets in the sterol biosynthesis pathway of Naegleria fowleri.

Authors:  Wenxu Zhou; Anjan Debnath; Gareth Jennings; Hye Jee Hahn; Boden H Vanderloop; Minu Chaudhuri; W David Nes; Larissa M Podust
Journal:  PLoS Pathog       Date:  2018-09-13       Impact factor: 6.823

8.  Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.

Authors:  Rafaella R Costa; João A Oliveira-da-Silva; Thiago A R Reis; Grasiele S V Tavares; Débora V C Mendonça; Camila S Freitas; Daniela P Lage; Vívian T Martins; Luciana M R Antinarelli; Amanda S Machado; Raquel S Bandeira; Fernanda Ludolf; Thaís T O Santos; Rory C F Brito; Maria V Humbert; Daniel Menezes-Souza; Mariana C Duarte; Miguel A Chávez-Fumagalli; Bruno M Roatt; Elaine S Coimbra; Eduardo A F Coelho
Journal:  Med Microbiol Immunol       Date:  2021-04-18       Impact factor: 3.402

9.  Cutaneous leishmaniasis due to Leishmania aethiopica: A therapeutic challenge.

Authors:  Laura Mengeot; Jean-Cyr Yombi; Marie Baeck
Journal:  JAAD Case Rep       Date:  2021-12-28

10.  Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.

Authors:  Xiaohua Zhu; Abdelbasset A Farahat; Meena Mattamana; April Joice; Trupti Pandharkar; Elizabeth Holt; Moloy Banerjee; Jamie L Gragg; Laixing Hu; Arvind Kumar; Sihyung Yang; Michael Zhuo Wang; David W Boykin; Karl A Werbovetz
Journal:  Bioorg Med Chem Lett       Date:  2016-03-25       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.